Ingrid Mayer
Faculty Member
Last active: 3/23/2014

  1. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE (2012) Magn Reson Med 68(1): 261-71
    › Primary publication · 22127821 (PubMed) · PMC3291742 (PubMed Central)
  2. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA, National Comprehensive Cancer Network (2012) J Natl Compr Canc Netw 10(7): 821-9
    › Primary publication · 22773798 (PubMed) · PMC3753191 (PubMed Central)
  3. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Abramson VG, Mayer IA (2012) Ther Adv Med Oncol 4(3): 139-47
    › Primary publication · 22590487 (PubMed) · PMC3349077 (PubMed Central)
  4. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL (2012) Mol Cancer Ther 11(10): 2301-5
    › Primary publication · 22879364 (PubMed) · PMC3682668 (PubMed Central)
  5. An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results. Li X, Abramson RG, Arlinghaus LR, Chakravarthy AB, Abramson V, Mayer I, Farley J, Delbeke D, Yankeelov TE (2012) EJNMMI Res 2(1): 62
    › Primary publication · 23157877 (PubMed) · PMC3520720 (PubMed Central)
  6. Motion correction in diffusion-weighted MRI of the breast at 3T. Arlinghaus LR, Welch EB, Chakravarthy AB, Xu L, Farley JS, Abramson VG, Grau AM, Kelley MC, Mayer IA, Means-Powell JA, Meszoely IM, Gore JC, Yankeelov TE (2011) J Magn Reson Imaging 33(5): 1063-70
    › Primary publication · 21509862 (PubMed) · PMC3081111 (PubMed Central)
  7. Invasive breast cancer. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R, National Comprehensive Cancer Network (2011) J Natl Compr Canc Netw 9(2): 136-222
    › Primary publication · 21310842 (PubMed)
  8. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE (2011) Breast Cancer Res Treat 126(1): 215-20
    › Primary publication · 20976543 (PubMed)
  9. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer. Abramson VG, Mayer IA (2011) Curr Treat Options Oncol 12(4): 403-11
    › Primary publication · 21918859 (PubMed)
  10. A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer. Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, Kelley MC, Meszoely IM, Means-Powell JA, Abramson VG, Grau AM, Gore JC, Yankeelov TE (2011) Phys Med Biol 56(17): 5753-69
    › Primary publication · 21841212 (PubMed) · PMC3176673 (PubMed Central)